Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
Curr Oncol
; 26(3): e418-e421, 2019 06.
Article
em En
| MEDLINE
| ID: mdl-31285688
ABSTRACT
Combination immune checkpoint blockade with concurrent administration of the anti-ctla4 antibody ipilimumab and the anti-PD-1 antibody nivolumab has demonstrated impressive responses in patients with advanced melanoma and other diseases. That combination has also been associated with increased toxicity, including rare immune-related adverse events. Here we describe a case of fatal steroid-refractory myocarditis and panmyositis associated with the use of this combination in a patient with metastatic melanoma. Correlative studies indicated increased levels of serum interleukin 6 in this patient at the onset of toxicity, suggesting a possible role for anti-interleukin 6 receptor antibodies in the treatment of subsequent cases of this rare, but fatal, toxicity.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Cutâneas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Ipilimumab
/
Antineoplásicos Imunológicos
/
Nivolumabe
/
Melanoma
/
Miocardite
/
Miosite
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Curr Oncol
Ano de publicação:
2019
Tipo de documento:
Article